AI summary · may contain errors
Safimaltib (JNJ-67856633) is a selective, allosteric MALT1 inhibitor that suppresses DLBCL and MCL cell growth at sub-micromolar doses and shows efficacy in mouse models.
- Open access
- 1 cites
American Association for Cancer Research · Oncology · ISSN 2643-3230, 2643-3249
Rebuilt
Newest first · last 60 days
AI summary · may contain errors
Safimaltib (JNJ-67856633) is a selective, allosteric MALT1 inhibitor that suppresses DLBCL and MCL cell growth at sub-micromolar doses and shows efficacy in mouse models.
AI summary · may contain errors
KHSRP is the top vulnerability in therapy-persistent acute myeloid leukemia, and its depletion sensitizes AML to treatment and substantially prolongs survival in treated AML-bearing mice.
AI summary · may contain errors
Dense tumor nodules in newly diagnosed multiple myeloma form a topographically defined TME enriched for macrophages, conventional dendritic cells, CD8+ T cells, endothelial cells, and THY1+ mesenchymal stromal cells.
AI summary · may contain errors
Quantitative CD19 density measured before CAR T-cell infusion stratifies progression-free survival in large B-cell lymphoma, with low CD19 density linked to CAR T-cell escape.
AI summary · may contain errors
Lower pretreatment tumor CD19 expression measured by flow cytometry is linked to worse 1-year progression-free survival after CD19 CAR T-cell therapy in LBCL, with 16% vs 64% for CD19low vs CD19high (P = 0.005).
AI summary · may contain errors
In multiple myeloma cells, PP1C dephosphorylates KRAS/NRAS T148 to enable LZTR1-dependent proteasomal degradation, while KRAS A146 gain-of-function mutations resist this pathway.
AI summary · may contain errors
An MPRA screen in CD34+ cells identified 87 regulatory noncoding variants across 32 CHIP-associated loci, including an MSI2 enhancer variant linked to clonal expansion of Tet2-deficient HSPCs.
AI summary · may contain errors
RHOA loss in large B-cell lymphomas downregulates CD19 and promotes CAR-19 T-cell resistance, with RHOA deficiency present in one in six newly diagnosed cases.
AI summary · may contain errors
In vivo CAR T-cell therapy in relapsed or refractory multiple myeloma is linked to deep responses and measurable residual disease negativity after BCMA-directed treatment, with durability shaped by host context.
AI summary · may contain errors
A posttranslational mechanism that regulates RAS stability is active almost exclusively in hematologic (heme) malignancies, highlighting a RAS hotspot mutation context in leukemia and myeloma.
AI summary · may contain errors
TAK-007, an off-the-shelf allogeneic CD19 CAR NK-cell therapy expressing IL-15, shows encouraging response rates with an excellent safety profile in heavily pretreated B-cell lymphoma, including post-CAR-T patients, though durability is limited.
AI summary · may contain errors
In 56 acute myeloid leukemia patients, AML-CAPP-Seq plasma ctDNA enabled universal MRD assessment with a median of 30.5 tracked variants per patient.
AI summary · may contain errors
Glofitamab-based therapy in 84 consecutive patients with relapsed or refractory CNS lymphoma produced high response rates, with PCNSL ORR 88% and CRR 59%.
AI summary · may contain errors
Safimaltib, a selective allosteric MALT1 protease inhibitor, shows potent antitumor activity in preclinical and clinical studies of B-cell non-Hodgkin lymphomas.
AI summary · may contain errors
Microenvironment classification is positioned as a key approach to personalize cell and immune therapies for large B-cell lymphoma, aiming to address the lack of durable benefit in most patients.
AI summary · may contain errors
In an open-label phase 2 trial in relapsed or refractory large B-cell lymphoma, prophylactic emapalumab before axi-cel did not prevent refractory high-grade ICANS/CRS-IEC-HS despite CAR T-cell expansion exceeding ZUMA-1 and a local standard-of-care cohort.
Journals this month
Topics moving, week to 17 Nov 2026
By field